Could a 3-Month Low-Dose blood thinner replace lifelong pills after heart procedure?
NCT ID NCT07575867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with atrial fibrillation can safely stop taking long-term blood thinners after a procedure that closes off a part of the heart called the left atrial appendage. Participants will get a reduced dose of the blood thinner apixaban for just 3 months after the procedure, then stop all blood thinners. The goal is to see if this approach is better than staying on standard-dose blood thinners forever, by comparing rates of bleeding, stroke, and other complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apixaban (reduced dose) and left atrial appendage closure device (Watchman FLX or Amplatzer Amulet)
What this could lead to
If successful, this could offer a way for people with atrial fibrillation to stop taking lifelong blood thinners after a heart procedure, reducing bleeding risk while still preventing strokes.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. The reduced-dose apixaban is only given for 3 months, and there is a risk of stroke or device complications if blood thinners are stopped too soon.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthсare of the Russian Federation
RECRUITINGMoscow, 101990, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••